Skip to main content

Alpha-Mannosidosis

7
Pipeline Programs
2
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Chiesi
ChiesiBrazil - Santana de Parnaíba
9 programs
2
5
LamazymPhase 31 trial
LamazymPhase 31 trial
LamazymPhase 31 trial
LamazymPhase 31 trial
Velmanase AlfaPhase 31 trial
+4 more programs
Active Trials
NCT06184503Recruiting5Est. Sep 2029
NCT04959240Available
NCT01681940Completed10Est. Sep 2013
+6 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Clinical Biomarkers in Alpha-mannosidosisN/A1 trial
Active Trials
NCT02141503Completed11Est. Nov 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
ChiesiVelmanase Alfa
ChiesiLamazym
ChiesiLamazym
ChiesiLamazym
ChiesiLamazym
ChiesiVelmanase Alfa
ChiesiLamazym
ChiesiVelmanase Alfa
Human BioSciencesClinical Biomarkers in Alpha-mannosidosis

Clinical Trials (10)

Total enrollment: 95 patients across 10 trials

NCT04031066ChiesiVelmanase Alfa

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis

Start: Jan 2021Est. completion: Dec 20210
Phase 3Withdrawn
NCT02478840ChiesiLamazym

Evaluation of Long-term Efficacy of Treatment With Lamazym

Start: Feb 2015Est. completion: Jun 201518 patients
Phase 3Completed
NCT01908712ChiesiLamazym

Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

Start: Aug 2013Est. completion: Sep 202213 patients
Phase 3Completed
NCT01908725ChiesiLamazym

Lamazym Aftercare Study

Start: Jun 2013Est. completion: Sep 20228 patients
Phase 3Completed
NCT01681953ChiesiLamazym

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

Start: Aug 2012Est. completion: May 201425 patients
Phase 3Completed
NCT02998879ChiesiVelmanase Alfa

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

Start: Dec 2016Est. completion: Jul 20205 patients
Phase 2Completed
NCT01681940ChiesiLamazym

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Start: Jan 2012Est. completion: Sep 201310 patients
Phase 2Completed
NCT04959240ChiesiVelmanase Alfa

Expanded Access to Velmanase Alfa

N/AAvailable
NCT06184503ChiesiVelmanase Alfa

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Start: Feb 2025Est. completion: Sep 20295 patients
N/ARecruiting
NCT02141503Human BioSciencesClinical Biomarkers in Alpha-mannosidosis

Clinical Biomarkers in Alpha-mannosidosis

Start: Jul 2014Est. completion: Nov 201911 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 95 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.